Table 1. The efficacy of TKIs against a panel of GBM cell lines.
| Drug | Targets | IC50 (μM) | |||
|---|---|---|---|---|---|
| U87 | LN-18 | U373 | A172 | ||
| Sorafenib | VEGFR-2 VEGFR-3 KIT PDGFR-β |
7.3 | 4.9 | 8.0 | 6.2 |
| Nilotinib | ABL1-2 PDGFR KIT BCR-ABL |
12.5 | 14.9 | >15 | 10.2 |
| Sunitinib | VEGFR-1-2 VEGFR-3 KIT PDGFR |
6.0 | 5.5 | >15 | 12.0 |
| Imatinib | ABL1-2 PDGFR KIT |
>15 | >15 | >15 | >15 |
| Gefitinib | EGFR | >15 | 12.2 | >15 | >15 |
| Lapatinib | EGFR ERBB2 |
12.5 | 7.0 | 12.6 | 12.4 |
| Dasatinib | ABL1-2 PDGFR KIT SRC |
0.31 | 0.25 | 0.5 | 2.35 |
| PD-173074 | FGFR-1 | 11.6 | 6.18 | 13.8 | 0.95 |
| Selumetinib | MEK | 14.75 | >15 | 11.9 | >15 |
| Crizotinib | Met ALK |
2.17 | 1.57 | 3.3 | 3.0 |
| Tofacitinib | JAK3 | >15 | >15 | >15 | >15 |
| Pazopanib | VEGFR-1-2 VEGFR-3 PDGFR KIT |
>15 | >15 | >15 | >15 |